The purpose of the study is to find out if the drug called “LNP023” is safe and has beneficial effects in people who have membranous nephropathy (MN) compared with rituximab.
MN is a disease of the kidney that causes an increase in the amount of protein eliminated in the urine.
The main objective of this research is to see whether taking LNP023 or rituximab for 6 months results in lower urine protein levels and to compare these two treatments in patients with MN.
Term of Use/Disclaimer
All information provided within this web and mobile application is intended for general information and is provided on the understanding that no surgical and medical advice or recommendation is being rendered. Please do not disregard the professional advice of your physician.
A/Prof Jason Choo Chon Jun
Singapore General Hospital
Published on 12 October 2020
Subscribe to our mailing list to get the updates to your inbox